Amgen to test psoriasis pill Otezla in COVID-19Amgen has announced it is developing its already marketed psoriasis drug Otezla as a potential treatment for COVID-19, the respiratory disease caused by Share XAmgen to test psoriasis pill Otezla in COVID-19https://pharmaphorum.com/news/amgen-to-test-psoriasis-pill-otezla-in-covid-19/
Amgen stumps up $13.4bn to claim Otezla from CelgeneCelgene has the buyer it needed for Otezla, smoothing the way for its mega-merger with Bristol-Myers Squibb. Amgen Share XAmgen stumps up $13.4bn to claim Otezla from Celgenehttps://pharmaphorum.com/news/amgen-stumps-up-13-4bn-to-claim-otezla-from-celgene/
Celgene gets new approval for soon-to-be-shed OtezlaCelgene has picked up a third approval for its anti-inflammatory drug Otezla, although it won’t reap much commercial Share XCelgene gets new approval for soon-to-be-shed Otezlahttps://pharmaphorum.com/news/celgene-gets-new-approval-for-soon-to-be-shed-otezla/
BMS will shed Otezla to push Celgene takeover throughBristol-Myers Squibb has opted to divest big-selling psoriasis drug Otezla to smooth the passage of its $74 billion Share XBMS will shed Otezla to push Celgene takeover throughhttps://pharmaphorum.com/news/bms-will-shed-otezla-to-push-celgene-takeover-through/
Otezla gains NICE approval for psoriatic arthritisEarlier decision to reject drug reversed. Share XOtezla gains NICE approval for psoriatic arthritishttps://pharmaphorum.com/news/otezla-gains-nice-approval-psoriatic-arthritis/
